Introduction
The sodium-independent glucose uansporter gene family comprises at least five genes encoding for GLUT-1 (erythroidlbrain type), GLUT-2 (liver type), GLUT-4 (insulin-responsive type), as well as other transporters that have been cloned from fetal skeletal muscle (GLUT-3) and intestinal (GLUT-5) cDNA libraries (Bell et al., 1990) . GLUT-1 is abundant in human erythrocytes as well as in cells actively dividing, such as in tissue culture (Baldwin and Lienhard, 1989; Mueckler et al., 1985) . Although GLUT-1 expression is virtually ubiquitous in cells grown in tissue culture (Bell et al., 1990) , the expression of this gene in vivo is restricted. Thus far, GLUT-1 has been found in epithelial barriers at the basolateral membrane and in endothelial barriers that contain tight junctions, such as the blood-brain barrier (BBB) or the blood-retinal barrier (Harik et al., 1990a; U a t a et al., 1990; Gerhart et al., 1989; Kalaria et al., 1988) . Exceptions to these pat- tions, such as testicular microvascular endothelium and endothelium on the fetal side of the syncytiotrophoblast of the placenta. In epithelial barriers, GLUT-1 was also found in the basolateral membrane of renal collecting duct epithelium, choroid plexus, and the placental syncytiotrophoblast layer. However, immunoreactive GLUT-1 was found in the apical membrane of ependymal epithelium near the lower portion of the third ventricle. In conclusion, there is diversity underlying the expression of the GLUT-1 glucose transporter protein in different cell types, and the transporter protein can be found in endothelium with and without occluding junctions, and in both apical and basolateral membranes of epithelial barriers. (J Hisrochem Cyrochem 40: FARRELL, YANG, PARDRIDGE rabbit immunoglobulin antiserum), immunogold-silver staining (IGSS) gelatin, and the Janssen IntenSE M Kit were purchased from Ted Pella (Redding, CA). Normal goat serum and the avidin-biotin-peroxidase (ABC) kit were purchased from Vector Laboratories (Burlingame, CA). The ultrapure bovine serum albumin (BSA), ovalbumin, and all other reagents were obtained from Sigma Chemicals (St Louis, MO). Adult male Sprague-Dawley rats (200 g) were purchased from Harlan Sprague-Dawley (Indianapolis, IN).
Fixation and Tissue
Processing for Light Microscopy. Unanesthetized, fed rats were decapitated and the brain, heart, testis, liver, kidney, lung, and spleen were removed, sliced into 4-mm thick blocks, and immersed in 2% paraformaldehyde in 0.01 M NaH2P04 (pH 7.4) containing 0.15 M NaCl (PBS) and fixed at 4'C for 3-4 hr. Human placenta and autopsy organs were immersion-fixed in 10% formalin. The tissues were then rinsed in 70% ethanol, dehydrated in an ethanol series, and embedded in paraffin. Sections 6-10 pm thick were cut on a microtome and placed on poly-L-lysine-coated slides and warmed to 55°C for 10-20 min. The slides were deparaffinized, rehydrated in ethanol, treated with 0.03% H202 for 5 min, and rinsed in PBS buffer. Nonspecific staining was blocked by incubating the sections with 5% goat serum in PBS for 30 min at room temperature. The excess serum was drained off and the primary or pre-immune rabbit antiserum was incubated overnight at 4'C at dilutions of either 1:750 or 1:lOOO in PBS. After incubation in the primary antiserum, the slides were rinsed in three changes of PBS buffer for 10 min each and were then processed for either the IGSS or the ABC immunostaining procedures described below.
IGSS Method. The original light-sensitive IGSS technique (Holgate et al., 1983) has been modified by Janssen Life Sciences (Olen, Belgium) to produce a light-insensitive method of silver enhancement. The initial stabilizer in the Intense-I1 protocol used by Bagley et al. (1989) , however, may have been subject to light-induced autonucleation of silver, and has undergone a proprietary modification resulting in the stabilizer of the In-tenSE M protocol Uanssen) used in the present studies.
The sections were treated with 20% normal goat serum in PBS for 30 min at room temperature and the secondary antibody, Auroprobe LM GAR diluted 1:50 or 1:75 in PBS and 0.01% IGSS gelatin, and 1% ultrapure BSA were applied and incubated for 40 min at room temperature. The slides were then washed three times in PBS buffer for 10 minutes each and washed extensively in distilled water before silver enhancement. Silver enhancement was performed according to the Janssen IGSS instruction manual by mixing equal volumes of Initiator and Enhancer solutions (from In-tenSE M Kit) and applying the mixture directly to the sections. Enhancement was followed by viewing the sections in the light microscope under low illumination. When the enhancement was complete (approximately 6-9 min), the sections were rinsed extensively in distilled water, some of the slides were lightly counterstained with Mayer's hematoxylin, and the slides were then dehydrated, cleared, and coverslipped.
Avidin-Biotin Immunopdtive Method. Avidin-biotin-peroxidase immunostaining (Hsu et al., 1981) was performed as described previously (Pardridge et al., 1990) , using the ABC (Elite) Kit from Vector and a primary or pre-immune antiserum dilution of 1:500.
Antiserum Preparation. A synthetic peptide corresponding to 13 amino acids at the C-terminus of the human brain glucose transporter (Mueckler et al., 1985) was coupled to bovine thyroglobulin using glutaraldehyde, and a rabbit polyclonal antiserum was prepared as described and characterized previously (Pardridge et al., 1990) . The antiserum was pre-absorbed with bovine thyroglobulin before all immunostaining as described previously, and is referred to as anti-CT antiserum (Pardridge et al., 1990) .
Results

IGSS Method
The specificity of the IGSS method as applied to the studies with the anti-CT antiserum was initially assessed by immunostaining GLUT-1 in rat kidney and rat liver. Similar to results reported previously with immunofluorescence methods (Tal et al., 1990; Thorens et al., 1990) , the immunoreactive GLUT-1 was found in the basolateral membrane of renal collecting duct epithelium ( Figure  1A ) and in the plasma membrane of perivenous hepatocytes (not shown). The immunostaining of GLUT-1 in rat brain with the IGSS method failed to detect measurable immunoreactive GLUT-1 in neuropil, although the microvascular endothelium contained immunoreactive GLUT-1 ( Figure 1B) . The minimal staining of the neuropil detected with the anti-CT antiserum was comparable to that found with pre-immune serum (not shown). Similar results were obtained after immunostaining of sections of mouse and human brain with the IGSS method. To test whether immunoreactive GLUT-1 was found in the microvascular endothelium in tissues other than brain, several rat organs were screened. No immunoreactive GLUT-1 was found in the microvascular endothelium in rat liver, kidney, heart, spleen, lung, or smooth muscle. However, microvascular endothelium was found to have abundant immunoreactive GLUT-1 in rat testis ( Figure IC) . High-power magnification of the IGSS staining for GLUT-1 showed that the immunoreactivity was confined to the endothelium lining the vascular wall and not to the microvascular smooth muscle ( Figure ID) .
Immunoperoxidase Method. Parallel studies with the IGSS and avidin-biotin-immunoperoxidase methods showed that the former was no more sensitive than the latter. Therefore, subsequent immunostaining was performed with the avidin-biotin-immunoperoxidase method. Immunoreactive GLUT-1 was found in choroid plexus epithelium and was localized to the basolateral membrane; conversely, choroidal vessels were not immunoreactive for GLUT-1 ( Figure 2A ). In general, the ependymal epithelium lining the ventricles removed from the choroid plexus lacked immunoreactive GLUT-1. However, the ependymal cells near the base of the third ventricle in either rat or mouse brain contained immunoreactive GLUT-1 ( Figures 2B-2D ). High-power magnification of the immunoreactive GLUT-1 in these ependyma showed that the transporter was localized to the apical but not the basolateral membrane, and that a contiguous capillary was immunoreactive for GLUT-1 ( Figure 2D ). In contrast, endothelia perfusing the choroid plexus (Figure 2A) were not immunoreactive for GLUT-1.
The presence of GLUT-1 in endothelium in human tissues was also examined using the following formalin-fixed, paraffinembedded autopsy specimens: kidney, adrenal gland, aorta, coronary artery, pituitary gland, thyroid gland, urinary bladder, spleen, trachea, prostate gland, and brain. In addition, human placenta was examined. Peripheral nerve perineurium was immunostained in the various organs, similar to previously reported observations (Gerhart and Drewes, 1990; Froehner et al., 1988) , and this served as an internal control on the respective slides to check the immunostaining reaction. No endothelial immunoreactive GLUT-1 was found in these human tissues, with the exception of brain and placenta. The endothelia of microvessels perfusing the fetal side of the trophoblast layer expressed immunoreactive GLUT-1 (Figure 3A) . Immunoreactive GLUT-1 was also abundant at the basal membrane of the syncytiotrophoblast layer of the placenta. No immunostaining was found in the microvillar brush border of the syncytiotrophoblast projecting into the maternal circulation ( Figure  3A) . No staining of lateral membranes in the trophoblast layer was Rat brain exhibits vascular immunoreactivity and negligible neuropil immunoreactivity that is no greater than that found with pre-immune serum (data not shown). found, owing to the syncytial nature of this epithelial barrier. No immunostaining was found in the placenta with the pre-immune serum ( Figure 3B ).
Discussion
The major findings of the present study are as follows. First, immunoreactive GLUT-1 is found in the basolateral membrane of epithelial barriers in kidney, choroid plexus, and placenta; however, the ependymal epithelial barrier near the base of the third ventricle contains abundant apical localization of immunoreactive GLUT-1. Second, GLUT-1 is actively expressed in the endothelium of microvessels perfusing the brain, which constitute the BBB in vivo. and these endothelial cells are fused by epithelium-like highresistance tight junctions (Brightman, 1977) ; however, there are at least two examples of immunoreactive GLUT-1 in endothelia that lack the tight junctions characteristic of the BBB. These examples are the testicular microvascular endothelium and the fetal endothelium of the trophoblast layer of the placenta. Third, the IGSS method has approximately the same sensitivity as the avidin-biotin-immunoperoxidase method and fails to show measurable GLUT-1 immunoreactivity in neuropil or brain astrocytes.
Previous studies have demonstrated diffuse GLUT-1 immunoreactivity in choroid plexus epithelium (Gerhart et al.. 1989; Kalaria et al., 1988) . The present study confirms a recent finding (Harik et al., 1990b) showing that this immunoreactivity is actually confined to the basolateral membrane of the choroid plexus epithelium. This cellular localization corroborates previous findings related to (a) asymmetric kinetics of glucose transport from CSF to blood vs glucose transport from blood to CSF (Deane and Segal, 1985) , and (b) previous immunocytochemical evidence show-ing localization of GLUT-1 immunoreactivity to the basolateral membrane of epithelial barriers such as in renal tubule . However, there are differences in the mechanism of sugar transport across the choroidal epithelial barrier vs the renal epithelial barrier. In the latter, glucose is reabsorbed against the concentration gradient via the combined action of a sodiumdependent glucose transporter at the apical membrane and a sodium-independent transporter at the basolateral membrane (Hediger et al., 1987) . In contrast, in choroid plexus glucose is secreted from blood into CSF space down a concentration gradient (Deane and Segal, 1985) . Therefore, the present findings of selective localization of the GLUT-1 glucose transporter at the basolateral membrane of choroid plexus epithelium suggest that other transporter proteins mediate glucose transport across the choroidal epithelial apical membrane.
The basolateral localization of immunoreactive GLUT-1 at choroid plexus epithelium contrasts with the apical immunolocalization of this transporter protein in ependymal epithelium lining regions of the third ventricle (Figure 2) . Choroidal epithelium has tight junctions that provide barrier properties segregating choroidal interstitial fluid from CSF (Brightman, 1977) . However, the ependymal epithelium removcd from circumventricular organs lacks tight junctions (Brightman, 1977) . Most ventricular ependymal cells are not immunoreactive for GLUT-1 (see Results). However, discrete regions of ventricular ependymal epithelium were densely immunoreactive on the apical membrane. The ependymal region immunoreactive for GLUT-1 was not at the median eminence region at the base of the third ventricle, as shown by the immunopositive capillary contiguous with the ependymal cells (Figure 2) . Microvessels perfusing choroid plexus were not immunoreactive for GLUT4 (Figure 2) . The function of GLUT-1 glucose transporters at the ap-FARRJXL, YANG, PARDRIDGE ical membrane of ventricular ependymal cells, which lack tight junctions (Brightman, 1977) , is at present unknown. However, the immunocytochemical results shown in Figure 2 illustrate the biological diversity underlying the localization of this cell membrane transport protein. The transporter can be localized to either basolateral membrane or apical membrane, and can be found in epithelium lacking tight junctions.
In addition to epithelial barriers lacking occluding junctions, immunoreactive GLUT-1 is also found in endothelial barriers lacking tight junctions, such as in testis or placenta (Figures 1 and 3) . These observations are in contrast to recent reports proposing that the expression ofthe GLUT-1 glucose transporter protein is restricted to epithelial and endothelial barriers possessing occluding or tight junctions (Harik et al., 1990a,b; U a t a et al., 1990) . In one study, immunoreactive GLUT-1 was not found in testicular microvascular endothelium of pre-pubertal4-8-week-old rats ( W t a et al., 1990) . However, the blood-testis barrier (BTB) does not develop until puberty (Setchell and Waites, 1975) . The BTB is formed by tight junctions adjoining Sertoli cells in human testis and by tight junctions within both Sertoli cells and microvascular smooth muscle cells in rat testis (Setchell and Waites, 1975) . In contrast, testicular endothelium lacks the tight junctions that are found in brain endothelium (Setchell and Waites, 1975; Brightman, 1977) . Since prepubertal rat testicular endothelium is not immunopositive for the GLUT-1 transporter protein (Takata et al., 1990) , the expression of testicular endothelial GLUT-1 may correlate with the development of the BTB at puberty. Another microvascular endothelium that expresses high quantities of immunoreactive GLUT-1 is the endothelium on the fetal side of the human placental trophoblast layer (Figure 3) . However, these endothelia lack occluding junctions (Yudilevich et al., 1979) . Indeed, the presence of occluding junctions in endothelium on the fetal side of the placenta would obstruct the free flow of nutrients from matemal to fetal circulation.
Finally, the present studies use the IGSS technique to show no measurable immunoreactive GLUT-1 in brain neuropil. With regard to this fmding, an important question in cerebral glucose transport biology is the nature of the glucose transporter mediating sugar uptake by neurons and glial cells. GLUT-1 was originally cloned from human hepatoma cells (Mueckler et al., 1985) and subsequently cloned from rat brain (Birnbaum et al., 1986) , and is often referred to as the brain type glucose transporter, which is synonymous with the GLUT-1 isoform (Bell et al., 1990) . Although original Northern blotting and immunocytochemical studies were consistent with an enrichment of GLUT-I at the microvascular endothelium (Kalaria et al., 1988; Flier et al., 1987) . it has generally been assumed that GLUT-1 also functions at brain cells. This assumption was supported by IGSS immunocytochemical studies showing marked GLUT4 immunostaining of rat brain neuropil (Bagley et al., 1989) . However, recent Northern blotting, in situ hybridization, and quantitative electron microscopic immunogold studies failed to find evidence for GLUT-1 gene expression in neurons or glial cells (Farrell and Pardridge, 1991; Boado and Pardridge, 1990a,b; Pardridge et al., 1990) . In addition, the IGSS results reported in the present study fail to find measurable GLUT-1 immunoreactivity in neuropil and confirm previous peroxidase immunocytochemical studies showing no measurable GLUT-1 immunoreactivity in neuropil (Pardridge et al., 1990) . The IGSS technique is subject to an increased background of light-induced "self-nucleation" of silver particles (see Materials and Methods). Therefore, methodological factors may explain the difference between the present study and the previous report using the IGSS technique in rat brain, since an improved stabilizer was used in these studies (see Materials and Methods). The hypothesis that GLUT-1 gene expression is restricted to the BBB in brain suggests the need for future studies identlfying novel neuronal and/or glial glucose transporters.
